Helpline
0800 121 8721
Email us
Donate

Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases

Home/Drug treatments/Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases

Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases

21 Jun 2019

Tags
brain metastases ipilimumab nivolumab Opdivo renal cell carcinoma Yervoy
Listen to this News
Print this News

Share this Page:

FacebookTwitterLinkedInWhatsAppTumblrPinterestVkXingEmail

An interim analysis of study Checkmate 920 has shown that patients with advanced renal cell carcinoma (RCC) and brain metastases may benefit from treatment with the ipilimumab/nivolumab combination therapy. The results from this interim analysis were presented at the 2019 American Society of Clinical Oncology (ASCO) in Chicago earlier this month.

Read more in Cancer Therapy Advisor here

Listen to this News
Print this News

Share this Page:

FacebookTwitterLinkedInWhatsAppTumblrPinterestVkXingEmail

Kidney cancer news

26 Sep 2023

Coalition for reducing bureaucracy in clinical trials

Read More

20 Sep 2023

Tips for staying strong with advanced kidney cancer

Read More

11 Sep 2023

Anticancer medication and risk of blood clots in hospitalised cancer patients with COVID-19

Read More

4 Sep 2023

Steve Pointon: Supporting people with person-centred counselling

Read More

21 Aug 2023

Leicester NHS Trust receives funding for robotic surgery theatre

Read More

21 Aug 2023

Belzutifan significantly delays progression of advanced kidney cancer after other treatments have failed

Read More

15 Aug 2023

Corticosteroids during treatment with nivolumab may not affect survival in kidney cancer

Read More

15 Aug 2023

How long side effects last after treatment with axitinib is stopped

Read More

26 Jul 2023

2022 National Cancer Patient Experience Survey

Read More

25 Jul 2023

Partial nephrectomy versus ablation for early stage kidney cancer in the elderly

Read More

19 Jul 2023

Early cancer detection test using ctDNA

Read More

19 Jul 2023

WECAN Academy 2023

Read More

Most used tags

renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent cabozantinib progression-free survival NHS England biomarkers ipilimumab Cabometyx pembrolizumab COVID-19 cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers targeted therapy papillary RCC everolimus Afinitor cancer outcomes ASCO first-line treatment partial nephrectomy NICE

Archives

Address

Action Kidney Cancer

11th Floor
3 Piccadilly Place
Manchester M1 3BN

Helpline

0800 121 8721
Email Us

About Action Kidney Cancer

We are the UK’s largest and most active patient-led kidney cancer charity. Whether you are a patient, survivor or someone you know has been diagnosed with kidney cancer, you have come to the right place to find support and information, and to be part of a caring and knowledgeable community of people: We are here to help you.
Registered charity in England, Wales (1164238), and Scotland (SC051330).
© Copyright Action Kidney Cancer 2021

Links

Home

About us

Donate

Contact us

Our partners

Branding by Kingswood Marketing

Policies

Website Policies

Complaints Policy

Equal Opportunities Policy

Information Governance Policy

Social Media Policy

Follow

X-Twitter

Web Design by Douglass Digital

Helpline: 0800 121 8721

support@actionkidneycancer.org

Go to Top